Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT168 in Adults Living With or Without HIV
NCT07698600Phase 1Recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BNT168 in human immunodeficiency virus infection (HIV) (7 arms), sponsored by BioNTech SE. Primary endpoints: Occurrence of at least one adverse event, Occurrence of at least one serious adverse event up to 12 months and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
BNT168
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07698600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698600.